Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-09-30
1997-06-17
Davenport, Avis M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 13, 514 14, 514 15, 514 16, 530324, 530325, 530326, 530327, 530328, A61K 3800, A61K 3802, C07K 500, C07K 700
Patent
active
056397267
ABSTRACT:
The invention relates generally to peptides which decrease the half-life of active plasminogen activator inhibitor-1. This invention further relates to methods and compositions for using peptides which decrease the half-life of active plasminogen activator inhibitor-1. Further, the invention includes methods and compositions useful in clot lysis.
REFERENCES:
patent: 4923807 (1990-05-01), Webb et al.
patent: 4929602 (1990-05-01), Harker et al.
patent: 4952512 (1990-08-01), Loskutoff et al.
patent: 5039791 (1991-08-01), Wittwer et al.
patent: 5057414 (1991-10-01), Stief et al.
patent: 5061693 (1991-10-01), Nutt et al.
patent: 5096811 (1992-03-01), Hotchkiss et al.
patent: 5106741 (1992-04-01), Marotti et al.
patent: 5134065 (1992-07-01), Sanzo et al.
Skeggs et al., J. of Exp. Med., vol. 106, pp. 439-453, 1957.
Oliner, Hypertension, vol. 11, No. 1, Jan. 1988 pp. 21-27.
Carrell et al., "Mobile Reactive Centre of Serpins and the Control of Thrombosis," Nature, 353:576-578, Oct. 1991.
Marder, "Inhibiting the Inhibitor," Circulation, 85:386-387, 1992.
Angleton PW, Chandler WL and Schmer G, Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79:101-106.
Bjork I, Ylinenjarvi K, Olson ST, and Bock PE, Conversion of antithrombin from an inhibitor of thrombin to a substrate with reduced heparin affinity and enhanced conformational stability by binding of a tetradecapeptide corresponding to the P.sub.1 to P.sub.14 region of the putative reactive bond loop of the inhibitor. J. Biol. Chem. 1992; 267:1976-1982.
Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, and Hantgan RR, Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: Light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81:1290-1299.
Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, De Mol M, et al., Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J. Clin. Invest. 1993; 92:2756-2760.
Erickson LA, Fici GJ, Lund JE, Boyle TP, Polites G, and Marotti KR, Development of venous occlusions in mice transgenic for the plasminogen activator inhibitor-1 gene. Nature 1990; 346:74-76.
Fay WP, Eitzman DT, Shaprio AD, Madison EL, and Ginsburg D, Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1 dependent and independent mechanisms. Blood 1994; 83:351-356.
Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, et al., cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J. Clin. Invest. 1986; 78:1673-1680.
Hamsten A, de Faire, Walldius G, Dahlen, Szamosi A, Landou C, Blomback M, and Wiman B, Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infraction. Lancet 1987; 2:3-9.
Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. New Engl. J. Med. 1985; 313:1557-1563.
Jang I-K, Gold HK, Ziskind AA, Fallon JT, Holt RE, Leinbach RC, et al., Differential sensitivity of erythrocyte-rich and platlet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation 1989; 79:920-928.
Lawrence DA, Olson ST, Palaniappan S, and Ginsburg D, Serpin reactive-center loop mobility is required for stable inhibition but not for enzyme recognition. J. Biol. Chem. 1994; 269;27657-27662.
Levi M, Biemond BJ, van Zonneveld A-J, Wouter Ten Cate J, and Pannekoek H, Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation 1992; 85:305-312.
Ny T, Sawdey M, Lawrence D, Millan JL, and Loskutoff DJ, Cloning and sequence of a cDNA coding for the human .beta.-migrating endothelial-cell-type plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA 1986; 83:6776-6780.
Potter van Loon BJ, Rijken DC, Brommer EJP and Van der Maas APC, The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost 1992; 67:101-105.
Reilly CF and Hutzelmann JE, Plasminogen activator inhibitor-1 binds to fibrin and inhibits tissue-type plasminogen activtor-mediated fibrin dissolution. J. Biol. Chem. 1992; 267:17128-17135.
Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, et al, Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc. Natl. Acad. Sci. USA 1992; 89:6998-7002.
Schulze AJ, Baumann U, Knof S, Jaeger E, Huber R, and Laurell C, Structural transition of a.sub.1 -antitrypsin by a peptide sequentially similar to .beta.-strand s4A. Eur. J. Biochem. 1990; 194:51-56.
Schulze AJ, Frohnert PW, Engh RA, and Huber R, Evidence for the extent of insertion of the active site loop of intact .alpha..sup.1 proteinase inhibitor in .beta.-sheet A. Biochem. 1992; 31:7560-7565.
Schulze AJ, Huber R, Bode W, and Engh RA, Structural aspects of serpin inhibition. Fed. of Eur. Biochem. Soc. 1994; 344:117-124.
Schulze AJ, Huber R, Degryse E, Speck D, and Bischoff R, Inhibitory activity and conformational transition of .alpha..sub.1 -proteinase inhibitor variants. Eur. J. Biochem. 1991; 202:1147-1155.
van Mourik JA, Lawrence DA, and Loskutoff DJ, Purification of an inhibitor plasminogen activator (anitactivator) synthesized by endothelial cells. J. Biol. Chem. 1984; 259:14914-14921.
Wiman M. and Hamsten A, The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Thromb Haemost 1990; 16:207-216.
Eitzman Daniel T.
Fay William P.
Francis-Chmura Ann Marie
Ginsburg David
Lawrence Daniel A.
Davenport Avis M.
Henry Ford Health System
The Regents of the University of Michigan
LandOfFree
Peptide mediated enhancement of thrombolysis methods and composi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide mediated enhancement of thrombolysis methods and composi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide mediated enhancement of thrombolysis methods and composi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2157796